Percent Free PSA
ورودیهای بالینی بیمار
حداقل ۰.۰۱ — حداکثر ۵۰ • واحد: ng/mL
حداقل ۰.۱ — حداکثر ۱۰۰ • واحد: ng/mL
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low25.1–100
- Intermediate10–25
- High0–9.9
The Percent Free PSA calculates evaluating lower urinary tract symptoms, nephrolithiasis burden, and prostate cancer risk. Key inputs include free psa. Scores guide initiating medical expulsive or alpha-blocker therapy, ordering renal imaging, or scheduling surgical intervention. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Percent free PSA = (free PSA / total PSA) × 100. In the total PSA 4-10 ng/mL range: >25% low, 10-25% intermediate, <10% high probability of prostate cancer on biopsy.
Clinical Indication
The Percent Free PSA is indicated for bedside clinical practice to support Percent free PSA = (free PSA / total PSA) × 100. In the total PSA 4-10 ng/mL range: >25% low, 10-25% intermediate, <10% high probability of prostate cancer on biopsy.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with renal colic, hematuria, benign prostatic hyperplasia (BPH), or urogenital malignancies. Clinical application is indicated across Urology clinics, shock wave lithotripsy suites, and acute urologic surgical services.
Limitations & Contraindications
Serum PSA levels can be transiently elevated by acute prostatitis, urinary retention, or recent instrumentation.
Clinical Pearls & Action Plan
Obstructive urolithiasis complicated by upper urinary tract infection represents a surgical emergency requiring urgent decompression.
%fPSA = (free / total) × 100.
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| free_psa | float | Yes | Free PSA(ng/mL) |
| total_psa | float | Yes | Total PSA(ng/mL) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 25.1–100 | Low | Low probability |
| 10–25 | Intermediate | Intermediate probability |
| 0–9.9 | High | High probability |
Evidence-Based References (EBM)
- Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA. 1998;279(19):1542-1547.